Personalis stock
PSNLNASDAQPersonalis, Inc., HealthcareISIN US71535D1063
41Score 41 out of 100, Weak
Price and trend
77 / 100
Price history
+98% in one yearThe chart shows daily closes over 7 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 37% above it.
Since June 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 50).
The price is 14% below its 52-week high. Largest decline in 7 years: 98% (January 2021 to October 2023).
Chart figures for advanced users
- SMA 50$16.10
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$11.54
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)50
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$5.04
- The lowest closing price of the last twelve months.
- Resistance$18.38
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Personalis, Inc. belongs to the Medical (Diagnostics & Research) industry (United States) and, with a market value of $1.72B, is number 31 of 37 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $69.65M (down 17.7% year on year) and a loss of $81.27M.
- For fiscal 2026, analysts expect on average revenue of $83M (up 19.2%) and adjusted earnings per share of −$1.09.
Show more
- MEQIRI Score 41 out of 100 (Weak): rank 533 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $190.6M, financial debt $37.2M.Stability 52
Weaknesses
- DilutionShare count up 160% since 2020.Capital allocation 18
- Loss-makingLoss of $119.33M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$107.69M over the last 12 months.Fundamentals 17
Its standout strengths are momentum and technical analysis, while fundamentals and profitability hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 16.9% on the twelve months before. Revenue has grown strongly since 2017, at around 28% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 23%, operating −126%, net −117%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 25 Feb 2027in 104 days
- Last reported
- 4 Nov 2026EPS reported −$0.32 (expected −$0.26)below expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 5.6% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$1.09−0.5%
- Revenue
- $83M+1.0%
- Earnings per share
- −$0.99−5.6%
- Revenue
- $109.74M−0.2%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −1.5%Full year guidance reaffirmed: revenue of $78 million to $80 million, gross margin of 15% to 20%.
“We expect total company revenue to be in the range of $78 million to $80 million, and this assumes clinical revenue of $10 million to $11 million specifically from breast and lung cancer surveillance tests recently covered by Medicare; revenue from pharma tests and services and all other customers to be in the range …”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 7 May 2026 (fiscal Q1 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 4 insiders sold, $7.62M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Hall Christopher MSale
3 Nov 2026, Chief Executive Officer
- Shares
- 29,112
- Price
- $15.87
- Value
- $462,007
- Moore Stephen MichaelSale
18 Sept 2026, SVP and Chief Legal Officer
- Shares
- 2,068
- Price
- $16.22
- Value
- $33,543
- Chen RichardSale
18 Sept 2026, President and CMO
- Shares
- 3,998
- Price
- $16.22
- Value
- $64,848
Show 10 more
- Hall Christopher MSale
18 Sept 2026, Chief Executive Officer
- Shares
- 7,459
- Price
- $16.22
- Value
- $120,985
- Tachibana AaronSale
18 Sept 2026, CFO AND COO
- Shares
- 2,931
- Price
- $16.22
- Value
- $47,541
- Chen RichardSale
15 Jul 2026, President and CMO
- Shares
- 100,000
- Price
- $15.15
- Value
- $1.52M
- Hall Christopher MSale
9 Jul 2026, Chief Executive Officer
- Shares
- 100,000
- Price
- $15.08
- Value
- $1.51M
- Tachibana AaronSale
29 Jun 2026, CFO AND COO
- Shares
- 4,982
- Price
- $14.00
- Value
- $69,748
- Tachibana AaronSale
26 Jun 2026, CFO AND COO
- Shares
- 51,251
- Price
- $13.18
- Value
- $675,488
- Hall Christopher MSale
26 Jun 2026, Chief Executive Officer
- Shares
- 100,000
- Price
- $13.15
- Value
- $1.32M
- Tachibana AaronSale
4 Jun 2026, CFO AND COO
- Shares
- 40,000
- Price
- $12.01
- Value
- $480,400
- Hall Christopher MSale
29 May 2026, Chief Executive Officer
- Shares
- 80,091
- Price
- $11.02
- Value
- $882,603
- Tachibana AaronSale
29 May 2026, CFO AND COO
- Shares
- 38,799
- Price
- $11.58
- Value
- $449,292
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Personalis
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 41
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Diagnostics & Research)
The next larger and next smaller companies by market value
- CareDxCDNA $4.19B59
- Vimian GroupVIMIAN.ST $2.23B58
- NeoGenomicsNEO $2.15B39
- VeracyteVCYT $1.99B53
- GeneDx HoldingsWGS $1.55B37
- OPKO HealthOPK $1.24B37
- Castle BiosciencesCSTL $1.06B45
- Fulgent GeneticsFLGT $694.28M36
ETFs that hold Personalis
Held by 10 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Genomics & Biotechnology UCITS ETFGN0M | 0.84% | 0.50% | €127.64M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.11% | 0.35% | €1.25B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.04% | 0.30% | €2.22B |
Show 5 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.04% | 0.30% | €4.28B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.01% | 0.35% | €8.27B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.01% | 0.43% | €2.5B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.00% | 0.30% | €964.08M |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.00% | 0.25% | €178.55M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Jun 2020)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.